ABSTRACT: Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent chronic liver disease that occurs in the setting of insulin resistance and increased adiposity. It has rapidly evolved into the most common liver disease seen in the pediatric population and is a management challenge for general pediatric practitioners, subspecialists, and for health systems. In this guideline, the expert committee on NAFLD reviewed and summarized the available literature, formulating recommendations to guide screening and clinical care of children with NAFLD.
*School of Medicine, Emory University
†Children's Healthcare of Atlanta, Atlanta, GA
‡Texas Children's Hospital
§Baylor College of Medicine, Houston, TX
||School of Medicine, Yale University, New Haven, CT
¶School of Medicine, University of Colorado, Denver
#Children's Hospital Colorado, Aurora, CO
**Cincinnati Children's Hospital Medical Center
††Department of Pediatrics, University of Cincinnati, Cincinnati, OH
‡‡Hospital for Sick Children
§§School of Medicine, University of Toronto, Toronto
||||Janeway Children's Health and Rehabilitation Centre
¶¶Discipline of Pediatrics, Faculty of Medicine, Memorial University of Newfoundland, St. John's, NL, Canada
##School of Medicine, University of California San Diego
***Rady Children's Hospital, San Diego, CA.
Address correspondence and reprint requests to Miriam B. Vos, MD, MSPH, FAHA, School of Medicine, Emory University, 1760 Haygood Dr, Atlanta, GA 30322 (e-mail: email@example.com).
Received 30 November, 2015
Accepted 22 November, 2016
The project was funded by the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) and grants DK096157, DK61731, and DK107243 (M.B.V.) and DK088925, DK088831, and DK61734 (J.B.S). The content is solely the responsibility of the authors and does not necessarily represent the official views of NASPGHAN or the AAP. This project was endorsed by the American Academy of Pediatrics.
M.B.V. has research funding from Resonance Health Inc, serves on a DSMB for Aegerion, and as a consultant for Shire, Immuron, Intercept, and Target Pharmasolutions. S.R.D. serves on a DMC for Novo Nordisk and consults for Sanofi. R.K. has research funding from Raptor. The remaining authors report no conflicts of interest.